Accessible Unlicensed Requires Authentication Published by De Gruyter January 5, 2018

Abiraterone acetate: a potential source of interference in testosterone assays

Benjamin P. Fairfax, Robert D. Morgan, Andrew Protheroe, Brian Shine and Timothy James

Corresponding author: Professor Andrew Protheroe, PhD FRCP, Department of Oncology, Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Old Road, Headington, Oxford OX3 7LE, UK, Phone: +44(0) 1865 235275

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Cancer Research UK Prostate Cancer Statistics, 2014. Search in Google Scholar

2. Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26(S5):v69–77. Search in Google Scholar

3. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447–54. Search in Google Scholar

4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005. Search in Google Scholar

5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368: 138–48. Search in Google Scholar

6. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, et al. Clinical and biochemical consequences of cyp17a1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012;97:507–16. Search in Google Scholar

Received: 2017-7-17
Accepted: 2017-11-27
Published Online: 2018-1-5
Published in Print: 2018-5-24

©2018 Walter de Gruyter GmbH, Berlin/Boston